Patients infected with the hepatitis C virus (HCV
H epatitis C is an infectious liver disease caused by the hepatitis C virus (HCV). The virus, which causes inflammation in the liver and can lead to more serious illness, primarily is spread by intravenous contact with the blood of an infected person. About 4 million people in the United States have been infected, making it the Nation's most common blood-borne disease, resulting in the deaths of between 10,000 and 12,000 people each year (National Institute of Diabetes and Digestive and Kidney Diseases 2003) . Those at heightened risk for HCV infection include intra venous drug users, people who received blood transfusions or organ transplants before 1992 or clotting factors made before 1987, health care workers who suffer needle-stick accidents, and infants born to mothers who are infected with HCV (Centers for Disease Con trol and Prevention 1998). Several factors may accelerate the progression of hepatitis C, including older age at the time of infection, male gender, obesity, abnormal accumulation of fat in the liver (a condition known as fatty liver, or steatosis), and excessive alco hol consumption (Poynard et al. 2001) .
This article discusses the mechanisms by which alcohol may exacerbate HCV-infected patients' risk of disease progression, reviews issues in the treatment of alcoholic patients with HCV infection, and addresses impor tant areas of future research.
Epidemiology of Hepatitis C Among Alcoholics
Almost one-third of alcoholics with clinical symptoms of liver disease have been infected with HCV, which is four times the rate of HCV infection found in alcoholics who do not have liver disease (Coelho-Little et al. 1995; Mendenhall et al. 1991; Takase et al. 1993) . As shown in figure 1, people with more severe liver disease are considerably more likely to test positive for HCV infection than those with less severe liver disease (Takase et al. 1993 ).
Hepatitis C and Alcohol

Figure 1
prevalence of HCV infection (as assessed by anti-HCV antibody tests).
SOURCE: Takase et al. 1993 . Patients with more severe alcoholic liver disease have a significantly higher Percent Positive for the Anti-HCV Antibody Years Since HCV Infection HCV + Alcohol than 40 g of alcohol per day, or 3.3 drinks, for women; and more than which fibrous scar tissue replaces healthy liver tissue), and liver cancer (specifically, hepatocellular carcinoma, the most common form of liver can cer). Although fewer studies have examined the effects of moderate drinking on the course of liver disease in HCV patients, there is some indi cation that alcohol consumption in the moderate-to-heavy range may increase HCV-infected patients' risk of developing liver fibrosis and cirrho sis. Research on whether gender has any effect on alcohol consumption and liver disease progression in HCV patients is very limited.
Alcoholic Fibrosis
Cirrhosis
In a study of 2,235 HCV-infected patients, Poynard and colleagues (1997) observed that patients who drank heav ily (more than 50 grams [g] of alcohol, or 4.2 drinks, per day 1 ) tended to show much more advanced liver scarring (i.e., fibrosis, a defining feature of cirrhosis) than those who did not drink as heavily. In addition, the researchers identified a group of "rapid fibrosers," who were more likely to be male, heavy drinkers, and infected with HCV after age 40.
Wiley and colleagues (1998) observed that HCV-infected patients who drank heavily were significantly more likely to develop cirrhosis than those who were not heavy drinkers. In addition, among patients who did develop cirrhosis, the disease emerged considerably sooner for patients who drank heavily than for those who did not (see figure 2) .
Bellentani and colleagues (1999) analyzed hepatitis virus markers (includ ing the virus's genetic material, HCV RNA, and antibodies to the virus), alcohol intake, and clinical and bio chemical evidence of liver disease in a random sample of 6,917 people in northern Italy. Regardless of HCV status, subjects who were heavy drinkers (which the authors defined as drink ing more than 30 g, or 2.5 drinks, 1 The National Institute on Alcohol Abuse and Alcoholism (NIAAA) defines a standard drink as 11-14 g of alcohol. This corresponds to approximately one shot of 80-proof alcohol (about 14 g alcohol), one glass of wine (11 g), or one 12-oz. beer (12.8 g).
per day) for more than 10 years were three times as likely to have cirrhosis than those who were not heavy drinkers. Among HCV-positive subjects, 32 percent of those who were heavy drinkers had cirrhosis, compared with 10 percent of those who were not heavy drinkers. There were five cases of hepatocellular carcinoma, all in the heavier drinking group.
Seeff and colleagues (2001) studied 1,030 patients who had been enrolled in a prospective investigation of transfusionassociated HCV conducted in the United States between 1968 and 1980. In a followup investigation conducted an average of 15 years after transfusions had occurred, the researchers found that 17 percent of patients infected with transfusion-associated HCV had developed cirrhosis, compared with 3.2 percent of patients with transfusion-associated non-A, non-B, and non-C hepatitis, and 2.8 percent of uninfected patients. Alcohol use greatly exacerbated patients' risk of progression from chronic hepatitis to cirrhosis. Patients with both transfusion-associated HCV and a history of heavy alcohol use were 31 times more likely to develop cirrhosis than control subjects without a history of alcohol abuse.
Perhaps the most dramatic demon stration that alcohol multiplies HCVinfected patients' risk of cirrhosis came from a study by Corrao and Arico (1998) . Of 285 cirrhotic subjects, only 1.4 percent (4 subjects) were HCV-positive and nondrinkers, compared with 11.2 percent (32 subjects) who were both HCV-positive and heavy drinkers.
People infected with both HCV and HIV are more likely to develop cirrhosis than are patients who are infected only with HCV, and alcoholism further potentiates this mechanism (Di Martino et al. 2001 ).
Liver Cancer
An Italian survey showed that alcohol intake doubles the risk of hepatocellular day (Donato et al. 2002) . Other research has shown that HCV-infected patients who drink heavily are more likely to develop liver cancer at a younger age than are those who drink less. For example, Noda and colleagues (1996) observed that patients who drank at least 46 g of alcohol (3.8 drinks) daily were diagnosed with hepatocellular carcinoma an average of 26 years after developing transfusion-associated HCV, whereas those who drank less than 46 g per day were diagnosed with cancer an average of 31 years after transfusion. And Kubo and colleagues (1997) found that, among HCV-infected patients with hepatocellular carcinoma, heavy drinkers had more advanced tumors and died sooner after diagno sis than did nondrinkers.
Moderate-to-Heavy Drinking and Disease Progression
Most studies have evaluated the effect of extremely heavy drinking on the progression of HCV infection to other liver disease, with little emphasis on the effects of moderate drinking on disease progression. However, some studies have found indications that moderate-to-heavy alcohol consump tion also may increase the risk of developing liver fibrosis and cirrhosis in patients infected with HCV.
Ostapowicz and colleagues (1998) specified no particular threshold level above which the risk of disease progres sion increases but found that, among patients with chronic HCV infection, those who had cirrhosis reported higher lifetime and total alcohol consump tion than those HCV patients who did not have cirrhosis.
Several other studies have examined the effects of moderate drinking on HCV progression.
2 Assessing HCVinfected patients who drank less than 40 g of alcohol (3.3 drinks) per day, Westin and colleagues (2002) found that patients whose alcohol intake was above the median level (4.8 g of alco hol, or less than one drink per day) showed more liver scarring (fibrosis) than patients whose alcohol consump tion was below the median level. Hézode and colleagues (2003) also found that the severity of fibrosis in patients with chronic HCV was corre lated with the amount of alcohol con sumed (see figure 3 ). Finally, a recent study of 180 patients with untreated chronic hepatitis C confirmed these findings (Zarski et al. 2003) .
Gender and Disease Progression
The data regarding the contribution of gender to the progression of HCV in alcoholics is quite limited. Chronic hepatitis C often is milder in women than in men, but women may be more sensitive than men to the adverse effects of alcohol (Becker et al. 1996) .
Histologic Features of Chronic Hepatitis C in Alcoholic Patients
As discussed above, there is strong evidence that heavy alcohol consumption-and perhaps even moderate consumption-increases the risk that HCV infection will progress to more serious liver disease. In patients infected with HCV, alcohol consumption has a direct effect on liver histology. Specifically, patients with HCV who are drinkers show greater liver necrosis, inflammation, fibrosis, and fatty infil tration than HCV patients who do not drink. Further, alcohol consump tion and fatty liver have been shown to act together to increase fibrosis in patients infected with HCV, especially in those who are obese and diabetic (Monto et al. 2002) .
Mechanisms of Liver Injury in Alcoholic Hepatitis C Infection
carcinoma in HCV-infected patients who drink 41 to 80 g of alcohol per day (between 3.4 and 6.7 drinks) and quadruples the risk for patients who drink more than 80 g of alcohol per
Although researchers do not fully understand how alcohol consumption accelerates liver injury in patients with HCV infection, it is likely that several factors are involved. The fol lowing mechanisms have been proposed:
• Increased replication of HCV in the liver. As illustrated in figure 4, some research (although not all) has found that greater alcohol consumption is related to higher HCV RNA blood concentrations (Pessione et al. 1998) . Moreover, as shown in figure 5 , when people infected with HCV who drank more than 10 g of alcohol (about 5.8 drinks) per day abstained from alcohol or substantially reduced their consumption for 4 months before treatment, HCV RNA levels dropped; the decline in serum HCV RNA among subjects who drank less than or equal to 10 g of alcohol (less than one drink) per day before abstaining was not statistically significant (Cromie et al. 1996) .
• Mutations of the HCV virus (forming what are known as quasi-species). Alcoholics infected with HCV show greater quasi-species complexity than do nonalcoholics with HCV infection. In alcoholic HCV patients, such increased viral complexity might make it difficult for the immune system to control the mutated viruses, leading to progressive injury (Takahashi et al. 2001 ).
• Increased programmed cell death (apoptosis) of liver cells. Apoptotic death of liver cells, which can ulti mately lead to liver fibrosis, is increased by alcohol consumption in people with HCV infection (Szabo 2003 ).
• Higher levels of inflammation and immunoregulatory proteins (specifi cally, interleukin, tumor necrosis factor, and interferon). In research with mice, Geissler and colleagues Hepatitis C and Alcohol (1997) noted that chronic alcohol feeding in mice inhibited immune responses (specifically, responses by T-helper cells and cytotoxic Tlymphocytes) that play a pivotal role in removal of HCV from the body (i.e., HCV clearance).
• Viral gene mutations.
• Fatty liver. Accumulation of fat in the liver is common in patients with HCV. Examining a large group of patients with HCV infection, Serfaty and colleagues (2002) found that fibrosis progressed about twice as quickly among drinkers with steatosis as among drinkers without steatosis or nondrinkers with or without steatosis.
• Accumulation of excess iron in body tissues (i.e., iron overload). Alcohol consumption increases iron stores in the liver, and iron overload seems to contribute to HCV disease progres sion by inducing fibrosis (Piperno et al. 1998 ).
• Oxidative stress. Alcohol stimulates the production of reactive oxygencontaining molecules (i.e., oxygen radicals). Heavy alcohol use also depletes the body's supply of molecules that normally defend tissues against damage caused by oxygen radicals (i.e., antioxidants). This state, known as oxidative stress, may accelerate liver damage in patients with HCV (Rigamonti et al. 2003 • Depression of the immune system by alcohol.
Treatment Issues
Heavy alcohol use can be detrimental to HCV-infected patients' long-term response to interferon therapy (see the sidebar for discussion of interferon treatment for HCV). It is likely that alcohol affects HCV treatment effec tiveness both because drinking tends to interfere with patients' adherence to therapy and because alcohol interferes with interferon therapy's antiviral actions.
Abstention Before Interferon Treatment
Some research has indicated that heavy drinkers who abstain from alcohol before interferon treatment respond better to treatment than do those who continue to drink. In one study, heavy drinkers who did not abstain from drinking before interferon treatment showed a total lack of HCV RNA clearance, whereas those who normally drank heavily but abstained from drinking before interferon treatment showed some improvement in HCV RNA clearance (and the virus completely disappeared in 15.8 percent of heavy drinkers who abstained before treat ment) (Mochida et al. 1996) .
However, this study indicated that when HCV-infected alcoholic patients who normally drank heavily (70 or more grams of alcohol, or at least 5.8 drinks, per day) abstained from alcohol consumption during interferon therapy, their rate of HCV RNA clearance was markedly lower than was the case for HCV-infected nondrinkers (see figure  6 ). These results were confirmed by a recent Italian study (Tabone et al. 2002) in which 150 patients with chronic HCV underwent interferon treatment abdominal pain, poor appetite, muscle and joint pain, or symptoms of the disease and can expect long-term . Data from a cohort of European patients with cirrhosis followed for an aver age of 5 years showed that only 7 percent developed hepatocellular carcinoma, and 18 percent experienced symptomatic liver failure (Fattovich et al. 1997 ).
There currently is no vaccine for hepatitis C.
Testing and Treatment
Blood tests can diagnose HCV infection, either by detecting antibodies to the virus or by detecting the presence and quantity of the virus's genetic material (HCV RNA) itself (National Institutes of Health 2002). Liver biopsy is quite helpful for evaluating the disease's severity prior to initiating treatment. Liver enzymes have little value in predicting fibrosis. There are six known genetic variants (genotypes) of HCV, which vary geographically in their rate of occurrence. Genotypes 1 (which accounts for 70 to 75 percent of cases), 2, and 3 constitute the majority of genotypes in the United States.
The standard treatment for symptomatic hepatitis C infection is a combination of the drugs pegylated interferon (peginterferon) and ribavirin (National Institutes of Health 2002). Strict abstinence from alcohol is important during treatment.
Currently, the best indicator of effective treatment is a sustained virological response (SVR), defined by the absence of detectable virus 24 weeks after the end of treatment. Early viral response (a minimum 2 log decrease in viral load during the first 12 weeks of treatment) is predictive of SVR, and patients who fail to achieve an early viral response at week 12 should discontinue the treatment. Genotype 1 requires 1 year of treatment, whereas genotypes 2 and 3 require a 6 month course. In research with patients who did not consume alcohol during the therapy, SVR rates of 42 to 46 percent for genotype 1 and 76 to 82 percent for genotypes 2 and 3 have been obtained (Di Bisceglie and Hoofnagle 2002) .
-Eugene R. Schiff and Nuri Ozden for 1 year after 6 months of abstinence from alcohol. (Abstinence was verified by analyzing blood levels of a biologi cal marker of heavy alcohol consump tion known as carbohydrate-deficient transferrin.) Although all patients had abstained from alcohol before beginning treatment, only 9 percent of (normally) heavy drinkers exhibited a sustained response to the interferon Hepatitis C and Alcohol treatment, compared with 20 percent of light drinkers and 33 percent of nondrinkers. The factors that most strongly predicted a poor response to interferon treatment were the specific type of HCV infection (patients with HCV genotype 1b were least respon sive), patients' age, and their lifetime alcohol intake.
Treatment Recommendations
The evidence is strong that continued heavy alcohol intake during interferon treatment adversely affects treatment effectiveness. Further, depression, irri tability, and anxiety-side effects that occur in 20 to 30 percent of patients who receive interferon treatmentmay be especially difficult to manage for patients with a history of alcoholism, predisposing them to begin drinking again (Zdilar et al. 2000) . Despite this risk, however, the data do not support withholding interferon therapy for chronic HCV from patients with a history of alcoholism or heavy drink ing if they remain abstinent and have adequate psychosocial support during treatment. Likewise, light-to-moderate drinkers should not be excluded from HCV treatment, nor should a period of abstinence before starting therapy be enforced in this patient population.
Directions for Future Research
A recent National Institute on Alcohol Abuse and Alcoholism conference (Mor gan et al. 2003) identified areas of research with the greatest potential for leading to more effective treatment options. Conference recommendations for research within these areas were as follows:
Clinical Studies
• Determine how variations in the amount and pattern of drinking, combined drinking and smoking, and nutritional deficiencies affect HCV-infected patients' risk of liver injury, disease progression, and death.
• Evaluate the effectiveness of alco hol cessation programs in patients with HCV.
• Specify how alcohol affects patients' response to interferon treatment, including chemical interactions and day-to-day changes in virus activity during treatment.
HCV Virology
• Determine how alcohol affects viral replication, clearance, and persistence and the evolution of new HCV quasi-species.
• Examine whether alcohol use leads to greater dominance of more harmful genetic variants of HCV.
• Determine whether alcohol inter acts with the HCV viral proteins to alter the virus's genetic activity.
Immunology
• Identify the effects of alcohol on immune responses to HCV, includ ing changes in quality, behavior, and survival of immune cell populations both within and outside the liver.
Mechanisms of Liver Injury
• Determine what factors activate the liver cells that deposit fibrous material at the site of injury and cause scarring (i.e., hepatic stellate cells). These fac tors may include the patient's immune response to HCV infection, the spe cific HCV genotype, and oxidative stress triggered by alcohol use.
• Identify factors (including comple mentary medicines) that may inhibit stellate cell activation and fibrosis in HCV-infected patients who use alcohol.
• Clarify the roles that alcohol and HCV infection play in oxidative stress, lipid peroxidation, and dis ruption of cell function.
• Determine the source of proteins, known as cytokines, that act as antibody-mediated (humoral) messengers between liver cells, and their role in liver cell injury and regeneration in HCV-infected patients who use alcohol.
• Evaluate the effect of alcohol and HCV infection on fatty liver and determine how steatosis contributes to liver disease.
• Determine how alcohol use and HCV infection influence various types of liver cells (i.e., hepatocytes, Kupffer cells, endothelial cells, and hepatic stellate cells).
• Characterize the effect of human liver cells (i.e., hepatocytes) on overall human pathophysiology in response to alcohol and HCV.
• Identify genetic factors that affect the severity of alcohol-and HCVinduced liver disease.
Model Systems
• Develop animal models (using living animals and laboratory cell cultures)
of HCV infection and of alcoholic liver disease that reproduce disease processes found in humans.
Summary
Excessive alcohol consumption among patients infected with chronic hepati tis C is likely to result in more severe liver injury, promoting cirrhosis and increasing the risk for development of liver cancer (specifically, hepatocellular carcinoma 
